ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Files An 8-K Entry into a Material Definitive Agreement

ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement

Story continues below

On July 3, 2017, Actinium Pharmaceuticals, Inc. (the “Company”) entered into an Amended and Restated At-the-Market Market Issuance Sales Agreement (the “Amended Agreement”) with FBR Capital Markets & Co. (“FBR”), JonesTrading Institutional Services LLC (“JonesTrading”), and MLV & Co. LLC (“MLV”). to the Amended Agreement, FBR and JonesTrading were added as agents to the original At-the-Market Issuance Sales Agreement, dated March 24, 2014 with MLV. Sales of the Company’s common stock through FBR. JonesTrading or MLV, if any, will be made on the NYSE MKT LLC, on any other existing trading market for the common stock or to or through a market maker. Subject to the terms and conditions of the Amended Agreement, the agents will use commercially reasonable efforts to sell the Company’s common stock from time to time, based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay to the agents in cash, upon the sale of common stock to the Amended Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock.A copy of the Amended Agreement will be included as an exhibit to the Company’s Form 10-Q for the quarter ending June 30, 2017.


Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.


ACTINIUM PHARMACEUTICALS, INC. (NYSEMKT:ATNM) closed its last trading session 00.00 at 1.22 with 78,953 shares trading hands.

An ad to help with our costs